Abstract
Purpose
Lipid suspensions have been shown to be a suitable bio-enabling formulation approach for highly lipophilic or ‘grease ball’ drug molecules, but studies on ‘brick dust’ drugs are lacking. This study explored the utility of lipid suspensions for enhancing oral bioavailability of the rather hydrophobic drug nilotinib in vivo in rats.
Methods
Four lipid suspensions were developed containing long chain triglycerides, medium chain triglyceride, long chain monoglycerides and medium chain monoglycerides and in vivo bioavailability was compared to an aqueous suspension. Additionally, in vitro lipolysis and wettability tests were conducted.
Results
Nilotinib lipid suspensions did not show a bioavailability increase compared to an aqueous suspension. The bioavailability was lower for triglyceride suspensions, relative to both monoglyceride and an aqueous suspension. The long chain monoglyceride displayed a significantly higher bioavailability relative to triglycerides. In vitro lipolysis results suggested entrapment of nilotinib crystals within poorly dispersible triglycerides, leading to slower nilotinib release and absorption. This was further supported by higher wettability of nilotinib by lipids.
Conclusion
Monoglycerides improved oral bioavailability of nilotinib in rats, relative to triglycerides. For ‘brick dust’ drugs formulated as lipid suspensions, poorly dispersible formulations may delay the release of drug crystals from the formulation leading to reduced absorption.
Similar content being viewed by others
References
Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci. 2010;99(12):4940–54.
Di L, Fish PV, Mano T. Bridging solubility between drug discovery and development. Drug Discov Today. 2012;17(9–10):486–95.
Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235–49.
Bergstrom CA, Yazdanian M. Lipophilicity in drug development: too much or not enough? AAPS J. 2016;18(5):1095–100.
Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000;11(Suppl 2):93–8.
Ditzinger F, Price DJ, Ilie AR, Kohl NJ, Jankovic S, Tsakiridou G, et al. Lipophilicity and hydrophobicity considerations in bio-enabling oral formulations approaches - a PEARRL review. J Pharm Pharmacol. 2018.
Bergstrom CA, Charman WN, Porter CJ. Computational prediction of formulation strategies for beyond-rule-of-5 compounds. Adv Drug Deliv Rev. 2016;101:6–21.
Alskar LC, Porter CJ, Bergstrom CA. Tools for early prediction of drug loading in lipid-based formulations. Mol Pharm. 2016;13(1):251–61.
Mao F, Kong Q, Ni W, Xu X, Ling D, Lu Z, et al. Melting point distribution analysis of globally approved and discontinued drugs: a research for improving the chance of success of drug design and discovery. ChemistryOpen. 2016;5(4):357–68.
Thomas N, Holm R, Garmer M, Karlsson JJ, Mullertz A, Rades T. Supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS) enhance the bioavailability of the poorly water-soluble drug simvastatin in dogs. AAPS J. 2013;15(1):219–27.
Thomas N, Holm R, Mullertz A, Rades T. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release. 2012;160(1):25–32.
Ferraz R, Branco LC, Prudencio C, Noronha JP, Petrovski Z. Ionic liquids as active pharmaceutical ingredients. ChemMedChem. 2011;6(6):975–85.
Hough WL, Rogers RD. Ionic liquids then and now: from solvents to materials to active pharmaceutical ingredients. B Chem Soc Jpn. 2007;80(12):2262–9.
Larsen AT, Holm R, Mullertz A. Solution or suspension - does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug. Eur J Pharm Biopharm. 2017;117:308–14.
O' Driscoll CM, Griffin BT. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations. Adv Drug Deliv Rev. 2008;60(6):617–24.
Kuentz M. Lipid-based formulations for oral delivery of lipophilic drugs. Drug Discov Today Technol. 2012;9(2):e71–e174.
Shah SM, Jain AS, Kaushik R, Nagarsenker MS, Nerurkar MJ. Preclinical formulations: insight, strategies, and practical considerations. AAPS PharmSciTech. 2014;15(5):1307–23.
O'Neil MJ. The Merck index. In: An encyclopedia of chemicals, drugs, and biologicals. Whitehouse Station: Merck; 2001.
Chakrabarti S, Belpaire FM. Biovailability of phenytoin in lipid containing dosage forms in rats. J Pharm Pharmacol. 1978;30(5):330–1.
Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm. 2007;67(1):96–105.
Larsen A, Holm R, Pedersen ML, Mullertz A. Lipid-based formulations for Danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis. Pharm Res-Dordr. 2008;25(12):2769–77.
Thomas N, Richter K, Pedersen TB, Holm R, Mullertz A, Rades T. In vitro lipolysis data does not adequately predict the in vivo performance of lipid-based drug delivery systems containing fenofibrate. AAPS J. 2014;16(3):539–49.
El-Laithy HM, Basalious EB, El-Hoseiny BM, Adel MM. Novel self-nanoemulsifying self-nanosuspension (SNESNS) for enhancing oral bioavailability of diacerein: simultaneous portal blood absorption and lymphatic delivery. Int J Pharm. 2015;490(1–2):146–54.
Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, et al. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol. 1994;37(1):13–20.
Carrigan PJ, Bates TR. Biopharmaceutics of drugs administered in lipid-containing dosage forms .1. Gi-absorption of Griseofulvin from an oil-in-water emulsion in rat. J Pharm Sci-Us. 1973;62(9):1476–9.
Guidechem. Nilotinib. Available from: https://www.guidechem.com/dictionary/en/641571-10-0.html. Accessed 14 Jan 2019.
Gautschi N, Bergstrom CA, Kuentz M. Rapid determination of drug solubilization versus supersaturation in natural and digested lipids. Int J Pharm. 2016;513(1–2):164–74.
Williams HD, Sassene P, Kleberg K, Bakala-N'Goma JC, Calderone M, Jannin V, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci. 2012;101(9):3360–80.
Williams HD, Sassene P, Kleberg K, Calderone M, Igonin A, Jule E, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations. Pharm Res. 2013;30(12):3059–76.
Muster TH, Prestidge CA. Water adsorption kinetics and contact angles of pharmaceutical powders. J Pharm Sci. 2005;94(4):861–72.
Pirro E, De Francia S, De Martino F, Fava C, Ulisciani S, Cambrin GR, et al. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. J Chromatogr Sci. 2011;49(10):753–7.
Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu CP, et al. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Mol Pharm. 2011;8(4):1292–302.
FDA. Nilotinib (Tasigna) - Clinical Pharmacology and Biopharmaceutics Review. U.S. Department of Health and Human Services. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022068toc.cfm. Accessed 01 October 2018
Xia B, Heimbach T, He H, Lin TH. Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability. Biopharm Drug Dispos. 2012;33(9):536–49.
European Pharmacopoeia Commission., Council of Europe. European pharmacopoeia 9.0, General notices; 2016.
Feeney OM, Crum MF, McEvoy CL, Trevaskis NL, Williams HD, Pouton CW, et al. 50 years of oral lipid-based formulations: provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016;101:167–94.
Stillhart C, Kuentz M. Trends in the assessment of drug supersaturation and precipitation in vitro using lipid-based delivery systems. J Pharm Sci. 2016;105(9):2468–76.
Griffin BT, Kuentz M, Vertzoni M, Kostewicz ES, Fei Y, Faisal W, et al. Comparison of in vitro tests at various levels of complexity for the prediction of in vivo performance of lipid-based formulations: case studies with fenofibrate. Eur J Pharm Biopharm. 2014;86(3):427–37.
Christophersen PC, Christiansen ML, Holm R, Kristensen J, Jacobsen J, Abrahamsson B, et al. Fed and fasted state gastro-intestinal in vitro lipolysis: in vitro in vivo relations of a conventional tablet, a SNEDDS and a solidified SNEDDS. Eur J Pharm Sci. 2014;57:232–9.
Smith BT. Physical pharmacy. London: Pharmaceutical Press; 2016.
Lentz KA. Current methods for predicting human food effect. AAPS J. 2008;10(2):282–8.
Holm R, Farver P, Müllertz A. Can human food effects be predicted in a rat model? In.American Association of Pharmaceutical Scientists annual meeting. San Diego: AAPS; 2017.
O'Shea JP, Holm R, O'Driscoll CM, Griffin BT. Food for thought: formulating away the food effect - a PEARRL review. J Pharm Pharmacol. 2018.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Koehl, N.J., Holm, R., Kuentz, M. et al. New Insights into Using Lipid Based Suspensions for ‘Brick Dust’ Molecules: Case Study of Nilotinib. Pharm Res 36, 56 (2019). https://doi.org/10.1007/s11095-019-2590-y
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11095-019-2590-y